Adam Grossman - ADMA Biologics President CEO, Director


USD 3.55  0.09  2.47%   

Mr. Adam S. Grossman is the President, Chief Executive Officer, Director and cofounder of ADMA Biologics, Inc. Mr. Grossman was a director of the Company since 2007, has served as the Companys President and Chief Executive Officer since October 2011 and as the Companys President and Chief Operating Officer between 2007 and October 2011. Mr. Grossman has over 20 years of experience in the blood and plasma industry. Prior to founding the Company, Mr. Grossman was the Executive Vice President of National Hospital Specialties at GenesisBPS, a position he held between 1994 and 2011. He has experience in launching new products, building and managing national and international sales forces, managing clinical trials and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, our Vice Chairman and cofounder. Mr. Grossman was chosen to serve on the Board because, as the Companys Chief Executive Officer, he is able to provide the Board with critical insight into the daytoday operations of the Company.
Age: 45  CEO Since 2011      
201 478 5552
Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University.

Adam Grossman Latest Insider Activity

Tracking and analyzing the buying and selling activities of Adam Grossman against ADMA Biologics stock is an integral part of due diligence when investing in ADMA Biologics. Adam Grossman insider activity provides valuable insight into whether ADMA Biologics is net buyers or sellers over its current business cycle. Note, ADMA Biologics insiders must abide by specific rules, including filing SEC forms every time they buy or sell ADMA Biologics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Grossman over six months ago via Macroaxis 
Adma Biologics exotic insider transaction detected
Adam Grossman over six months ago via Macroaxis 
Adma Biologics exotic insider transaction detected

ADMA Biologics Management Efficiency

ADMA Biologics has return on total asset (ROA) of (0.1078) % which means that it has lost $0.1078 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.6923) %, meaning that it created substantial loss on money invested by shareholders. ADMA Biologics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of December 9, 2022, Return on Investment is expected to decline to -30.19. In addition to that, Return on Average Assets is expected to decline to -31.95. ADMA Biologics Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 276.25 Million. The current year Current Assets is expected to grow to about 225.2 M, whereas Revenue to Assets are forecasted to decline to 0.25.
The company currently holds 94.87 M in liabilities with Debt to Equity (D/E) ratio of 1.32, which is about average as compared to similar companies. ADMA Biologics has a current ratio of 7.78, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ADMA Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, ADMA Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ADMA Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ADMA Biologics to invest in growth at high rates of return. When we think about ADMA Biologics' use of debt, we should always consider it together with cash and equity.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Adma Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 527 people. ADMA Biologics (ADMA) is traded on NASDAQ Exchange in USA and employs 527 people.

ADMA Biologics Leadership Team

Elected by the shareholders, the ADMA Biologics' board of directors comprises two types of representatives: ADMA Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ADMA Biologics. The board's role is to monitor ADMA Biologics' management team and ensure that shareholders' interests are well served. ADMA Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ADMA Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Eric Richman, Independent Director
Michael Goldstein, Sr Counsel
Neal Fitzpatrick, VP Sales
Brian Lenz, CFO
Kaitlin Kestenberg, Project Compliance
Cyndi Tolman, VP Services
Alan Erck, VP of Sales and National Accounts
Dr DPS, CoFounder Chairman
Jerrold Grossman, Vice Chairman of the Board
Dov Goldstein, Independent Director
Bernhard Ehmer, Director
Steven Elms, Chairman of the Board
Adam Grossman, President CEO, Director
Drew Pantello, VP Devel
PharmD BCOP, Ex Engagement
James Mond, Chief Scientific and Medical Officer
Bryant Fong, Independent Director
Michael Least, VP Operations
Lawrence Guiheen, Independent Director

ADMA Biologics Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ADMA Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

ADMA Biologics Investors Sentiment

The influence of ADMA Biologics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in ADMA Biologics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to ADMA Biologics' public news can be used to forecast risks associated with investment in ADMA Biologics. The trend in average sentiment can be used to explain how an investor holding ADMA Biologics can time the market purely based on public headlines and social activities around ADMA Biologics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
ADMA Biologics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ADMA Biologics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average ADMA Biologics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on ADMA Biologics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ADMA Biologics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ADMA Biologics' short interest history, or implied volatility extrapolated from ADMA Biologics options trading.
Please continue to Trending Equities. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.